Contemporary Therapeutic Strategies for Solid Tumors

A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".

Deadline for manuscript submissions: 26 July 2026 | Viewed by 355

Special Issue Editor


E-Mail Website
Guest Editor
Triservice General Hospital Taiwan, National Defense Medical Center, Taipei, Taiwan
Interests: hematologic malignancies; stem cell transplantation; immunotherapy; CAR-T cell therapy; multiple myeloma; leukemia and lymphoma; precision medicine; novel therapeutics; hematopoietic stem cells; drug resistance in cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue addresses contemporary therapeutic strategies and survival outcomes in severe diseases, with a primary focus on solid tumors. As advances in cancer treatment continue to evolve rapidly, there is a critical need to evaluate both innovative therapeutic approaches and their impact on patient survival and long-term outcomes.

We invite original research articles, systematic reviews, meta-analyses, and clinical studies that examine cutting-edge treatment modalities and survival analysis across a diverse range of solid tumors, including but not limited to nasopharyngeal carcinoma, rectal cancer, breast cancer, lung cancer, gastric cancer, and hepatocellular carcinoma. This Special Issue particularly welcomes submissions exploring targeted therapy, immunotherapy, precision medicine, combination treatment regimens, and emerging cellular therapies for solid tumors, alongside comprehensive survival analyses that provide insights into prognostic factors and treatment efficacy.

The scope encompasses both prospective and retrospective studies that evaluate treatment outcomes for solid tumors, comparative effectiveness research, real-world evidence, and translational studies bridging laboratory discoveries to clinical applications. We encourage investigations into treatment-related survival benefits, quality of life assessments, biomarker-guided therapeutic decisions, and strategies to overcome treatment resistance in the context of solid malignancies.

This Special Issue aims to serve as a comprehensive resource for clinical physicians, oncologists, and researchers seeking to understand current best practices and emerging paradigms in the management of solid tumors. By integrating therapeutic innovation with rigorous survival analysis, we hope to contribute meaningful insights that will enhance clinical decision-making and ultimately improve patient outcomes in the face of these life-threatening malignancies.

Dr. Chohao Lee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic strategies
  • survival analysis
  • solid tumors
  • cancer treatment
  • targeted therapy
  • immunotherapy
  • precision medicine
  • clinical outcomes
  • prognostic factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 1246 KB  
Article
Adjuvant Tegafur-Uracil Improves Survival in Low-Risk, Mismatch Repair Proficient Stage IIA Colon Cancer: A Propensity Score-Matched Analysis
by Min-Chi Cheng, Hsu-Lin Lee, Shiue-Wei Lai, Jia-Hong Chen and Po-Huang Chen
Life 2025, 15(12), 1930; https://doi.org/10.3390/life15121930 - 17 Dec 2025
Viewed by 230
Abstract
Background: The benefit of adjuvant chemotherapy for low-risk, mismatch repair proficient (pMMR) stage IIA colon cancer is uncertain. Surveillance is standard, but some patients relapse. Tegafur-uracil (UFT) is a low-toxicity oral option that may offer benefit; Methods: This retrospective study included [...] Read more.
Background: The benefit of adjuvant chemotherapy for low-risk, mismatch repair proficient (pMMR) stage IIA colon cancer is uncertain. Surveillance is standard, but some patients relapse. Tegafur-uracil (UFT) is a low-toxicity oral option that may offer benefit; Methods: This retrospective study included patients with resected low-risk, pMMR stage IIA colon cancer (2013–2022). Patients receiving ≥5 postoperative UFT prescriptions were compared with those under surveillance. Propensity score matching (1:1) was applied, and disease-free survival (DFS) and overall survival (OS) were analyzed using Kaplan–Meier and Cox models with sensitivity analyses.; Results: Among 279 eligible patients, 71 matched pairs were analyzed. UFT reduced the risk of recurrence or death by 57% (DFS HR = 0.43, 95% CI 0.25–0.75, p = 0.002) and mortality by 62% (OS HR = 0.38, 95% CI 0.21–0.68, p < 0.001); Conclusions: UFT improved DFS and OS in low-risk pMMR stage IIA colon cancer, suggesting surveillance alone may undertreat some patients. Prospective trials are warranted. Full article
(This article belongs to the Special Issue Contemporary Therapeutic Strategies for Solid Tumors)
Show Figures

Figure 1

Back to TopTop